1-20 of 26
Stephen J. Schuster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration

Nektarios Kostopoulos, Francesca Costabile, Elisavet Krimitza, Silvia Beghi, Denisa Goia, Renzo Perales-Linares, George Thyfronitis, Michael J. LaRiviere, Elise A. Chong, Stephen J. Schuster, Amit Maity, Constantinos Koumenis, John P. Plastaras, Andrea Facciabene
Journal: Blood Advances
Blood Adv (2024) 8 (24): 6308–6320.
https://doi.org/10.1182/bloodadvances.2024012599
Published: 2024
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis

Clinical Trials & Observations
Peter A. Riedell, Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna De Abia, Nausheen Ahmed, Richard T. Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J. Schuster, Andy I. Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P. McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood Advances
Blood Adv bloodadvances.2024014164.
https://doi.org/10.1182/bloodadvances.2024014164
Published: 2024
Includes: Supplemental data
Journal Articles

Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Clinical Trials & Observations
Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua Elizabeth Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R Chong, Stephen J. Schuster
Journal: Blood Advances
Blood Adv bloodadvances.2024013640.
https://doi.org/10.1182/bloodadvances.2024013640
Published: 2024
Includes: Supplemental data
Journal Articles

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L. Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R. Bishop, Joseph P. McGuirk, Peter A. Riedell
Journal: Blood Advances
Blood Adv (2024) 8 (20): 5346–5354.
https://doi.org/10.1182/bloodadvances.2023012549
Published: 2024
Includes: Supplemental data
Journal Articles

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Clinical Trials & Observations
Rahul S. Bhansali, Fredrik Ellin, Thomas Relander, Miao Cao, Wenrui Li, Qi Long, Nivetha Ganesan, Robert Stuver, Steven M. Horwitz, Kitsada Wudhikarn, Steven R. Hwang, N. Nora Bennani, Julio Chavez, Lubomir Sokol, Hayder Saeed, Frank Duan, Pierluigi Porcu, Priyanka Pullarkat, Neha Mehta-Shah, Jasmine M. Zain, Miguel Ruiz, Jonathan E. Brammer, Rishab Prakash, Swaminathan P. Iyer, Adam J. Olszewski, Ajay Major, Peter A. Riedell, Sonali M. Smith, Caroline Goldin, Bradley Haverkos, Bei Hu, Tony Z. Zhuang, Pamela B. Allen, Wael Toama, Murali Janakiram, Taylor R. Brooks, Deepa Jagadeesh, Nisha Hariharan, Aaron M. Goodman, Gabrielle Hartman, Paola Ghione, Fatima Fayyaz, Joanna M. Rhodes, Elise A. Chong, James N. Gerson, Daniel J. Landsburg, Sunita D. Nasta, Stephen J. Schuster, Jakub Svoboda, Mats Jerkeman, Stefan K. Barta
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3507–3518.
https://doi.org/10.1182/bloodadvances.2024012800
Published: 2024
Includes: Supplemental data
Journal Articles

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

Clinical Trials & Observations
Guido Ghilardi, Luca Paruzzo, Jakub Svoboda, Elise A. Chong, Alexander A. Shestov, Linhui Chen, Ivan J. Cohen, Giulia Gabrielli, Sunita D. Nasta, Patrizia Porazzi, Daniel J. Landsburg, James N. Gerson, Jordan Carter, Stefan K. Barta, Rebecca Yelton, Raymone Pajarillo, Vrutti Patel, Griffin White, Hatcher J. Ballard, Elizabeth Weber, Ellen Napier, Emeline R. Chong, Joseph A. Fraietta, Alfred L. Garfall, David L. Porter, Michael C. Milone, Roderick O’Connor, Stephen J. Schuster, Marco Ruella
Journal: Blood Advances
Blood Adv (2024) 8 (3): 653–666.
https://doi.org/10.1182/bloodadvances.2023011492
Published: 2024
Includes: Supplemental data
Journal Articles

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era

Daniel J. Landsburg, Jennifer JD Morrissette, Sunita D. Nasta, Stefan K. Barta, Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Adam Bagg
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7243–7253.
https://doi.org/10.1182/bloodadvances.2023011384
Published: 2023
Includes: Supplemental data
Journal Articles

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

Clinical Trials & Observations
Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J. Schuster, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, John P. Leonard, Peter Martin, Jia Ruan
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6579–6588.
https://doi.org/10.1182/bloodadvances.2023010606
Published: 2023
Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Michael Scordo, Jessica R. Flynn, Mithat Gonen, Sean M. Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph Maakaron, Richard T. Maziarz, Andy I. Chen, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5579–5585.
https://doi.org/10.1182/bloodadvances.2023010302
Published: 2023
Includes: Supplemental data
Journal Articles

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-Soo Yoon, Carlos Panizo, Ian Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4926–4935.
https://doi.org/10.1182/bloodadvances.2022009260
Published: 2023
Includes: Supplemental data
Journal Articles

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Shakthi T. Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy I. Chen, Veronika Bachanova, Joseph E. Maakaron, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4765–4772.
https://doi.org/10.1182/bloodadvances.2022008937
Published: 2023
Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Clinical Trials & Observations
Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3192–3198.
https://doi.org/10.1182/bloodadvances.2022008294
Published: 2023
Includes: Supplemental data
Journal Articles

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones

Lauren C. Shaw, Mathilde Poussin, Alba Rodriguez-Garcia, Joshua Eggold, Nicholas G. Minutolo, Jie Wang, Alain H. Rook, Stephen J. Schuster, Daniel J. Powell, Jr
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1885–1898.
https://doi.org/10.1182/bloodadvances.2022008798
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, Brian K. Link
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5835–5843.
https://doi.org/10.1182/bloodadvances.2022008150
Published: 2022
Journal Articles

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

Clinical Trials & Observations
Saar Gill, Vanessa Vides, Noelle V. Frey, Elizabeth O. Hexner, Susan Metzger, Megan O'Brien, Wei-Ting Hwang, Jennifer L. Brogdon, Megan M. Davis, Joseph A. Fraietta, Avery L. Gaymon, Whitney L. Gladney, Simon F. Lacey, Anne Lamontagne, Anthony R. Mato, Marcela V. Maus, J. Joseph Melenhorst, Edward Pequignot, Marco Ruella, Maksim Shestov, John C. Byrd, Stephen J. Schuster, Donald L. Siegel, Bruce L. Levine, Carl H. June, David L. Porter
Journal: Blood Advances
Blood Adv (2022) 6 (21): 5774–5785.
https://doi.org/10.1182/bloodadvances.2022007317
Published: 2022
Includes: Supplemental data
Journal Articles

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4816–4820.
https://doi.org/10.1182/bloodadvances.2021006193
Published: 2022
Includes: Supplemental data
Journal Articles

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Clinical Trials & Observations
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4553–4557.
https://doi.org/10.1182/bloodadvances.2022007812
Published: 2022
Journal Articles

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

Clinical Trials & Observations
Karen Thudium Mueller, Stephan A. Grupp, Shannon L. Maude, John E. Levine, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, G. Doug Myers, Constantine S. Tam, Ulrich Jaeger, Stephen Ronan Foley, Peter Borchmann, Stephen J. Schuster, Edmund K. Waller, Rakesh Awasthi, Bernd Potthoff, Andy Warren, Edward R. Waldron, Fraser McBlane, Andrea Chassot-Agostinho, Theodore W. Laetsch
Journal: Blood Advances
Blood Adv (2021) 5 (23): 4980–4991.
https://doi.org/10.1182/bloodadvances.2020003844
Published: 2021
Includes: Supplemental data
Journal Articles

Stable HLA antibodies following sustained CD19 + cell depletion implicate a long-lived plasma cell source

Clinical Trials & Observations
Zheng Zhang, Stephen J. Schuster, Simon F. Lacey, Michael C. Milone, Dimitri Monos, Vijay G. Bhoj
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4292–4295.
https://doi.org/10.1182/bloodadvances.2020002435
Published: 2020
Journal Articles

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1440–1447.
https://doi.org/10.1182/bloodadvances.2019001305
Published: 2020
Includes: Supplemental data